Core Insights - Cumberland Pharmaceuticals reported a 31% increase in fourth quarter 2025 net revenues, totaling $13.7 million, compared to the same period last year [1] - For the full year 2025, net revenues reached $44.5 million, an 18% increase year-over-year, achieving the company's goal of double-digit revenue growth [1] - The company ended 2025 with total assets of $76.8 million, liabilities of $52.3 million, and shareholders' equity of $24.9 million [1] Financial Performance - The net loss for 2025 was $2.9 million, an improvement of $3.6 million from the previous year [1] - Adjusted earnings for the year were $1.7 million, reflecting a $2.7 million improvement over 2024 [1] - Cash flow from operations was $4.9 million in 2025, representing a $5.5 million increase compared to 2024 [1] International Expansion - In February 2025, Cumberland's Vibativ® received approval in China, with SciClone Pharmaceuticals granted exclusive rights for registration and distribution [1] - The launch of Vibativ in Saudi Arabia occurred in September 2025, following an agreement with Tabuk Pharmaceutical Manufacturing Company [1] - In October 2025, Cumberland's ibuprofen injection product received regulatory approval in Mexico, with PiSA Farmaceutica obtaining exclusive distribution rights [1] Expanded Commercial Portfolio - Cumberland announced a co-commercialization agreement with RedHill Biopharma Ltd. for Talicia®, an FDA-approved treatment for H. pylori infection [1] - Talicia is now recommended as a first-line therapy in the American College of Gastroenterology clinical guidelines and is patent protected until 2042 [1] Reimbursement Milestones - Caldolor® received a permanent J-code (J1741) in December 2025, facilitating a defined reimbursement pathway for healthcare providers [1] - This milestone supports the adoption of Caldolor as a non-opioid option for pain management, enhancing access for patients [1] Clinical Developments - Cumberland announced positive top-line results from the FIGHT DMD clinical trial for ifetroban, a treatment for Duchenne muscular dystrophy heart disease [1] - The trial showed significant improvements in left ventricular ejection fractions (LVEF) for patients treated with high-dose ifetroban compared to controls [1] - Ifetroban received Orphan Drug and Rare Pediatric Disease designations from the FDA, along with Fast Track Designation for further development [1]

Core Viewpoint - Cumberland Pharmaceuticals Inc. will announce its 2025 financial results and provide a company update on March 3, 2026, after market close, followed by a conference call to discuss the results [1] Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on developing, acquiring, and commercializing products for hospital acute care, gastroenterology, and oncology market segments [1] - The company’s portfolio includes several FDA-approved products such as Talicia®, Vibativ®, Vaprisol®, Sancuso®, Kristalose®, Caldolor®, and Acetadote® [1] Product Details - Talicia® is an oral capsule for treating H. pylori infection - Vibativ® is an injection for serious bacterial infections, including hospital-acquired pneumonia - Vaprisol® is an injection used to raise serum sodium levels in hospitalized patients - Sancuso® is a transdermal system for preventing nausea and vomiting in chemotherapy patients - Kristalose® is a prescription laxative for treating constipation - Caldolor® is an injection for pain and fever management - Acetadote® is an injection for treating acetaminophen poisoning [1] Clinical Programs - The company is conducting Phase II clinical programs for its ifetroban product candidate, targeting conditions such as Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis [1]

Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company with a portfolio of FDA-approved branded products [6] - The company has three national sales divisions and several catalysts for new growth opportunities [6] - Cumberland has a proven record of successful product development and product acquisition [6] Product Portfolio - Acetadote is an IV treatment for acetaminophen overdose, developed and registered by Cumberland [11] - Caldolor is an injectable delivery of ibuprofen with antipyretic, analgesic & anti-inflammatory properties, approved for use in adults, children and newborns [15] - Kristalose is a unique crystalline formulation of lactulose, a prescription strength laxative [20] - Vibativ is an IV antibiotic that treats life-threatening infections resulting from gram-positive bacteria [24] - Sancuso is an FDA-approved transdermal system for chemotherapy-induced nausea and vomiting [29] - Ifetroban is Cumberland's first new chemical entity, a potent, selective antagonist of thromboxane receptor [30] Financial Performance (2024) - Net revenues were $37.9 million [51] - Gross profit was $31.3 million [51] - Adjusted earnings were $(1.0) million [51] - Cash and securities totaled $18.0 million as of December 31, 2024 [52] - The company has tax carryforward credits of $53 million available [52]